Dr. Crafton on Optimizing Treatment Selection in Recurrent Ovarian Cancer

Sarah Crafton, MD
Published: Wednesday, Nov 27, 2019



Sarah Crafton, MD, gynecologic oncologist, Allegheny Health Network, discusses optimizing treatment selection in recurrent ovarian cancer.
 
Platinum-sensitivity should be used to guide treatment selection in the recurrent setting, says Crafton. Notably, a variety of platinum-based therapies and targeted therapies are available to patients with platinum-sensitive disease. and platinum-resistant disease.
 
The National Comprehensive Cancer Network publishes a list of available agents for patients with platinum-sensitive and platinum-resistant disease. The decision of which treatment to pursue should be based on previous toxicities, disease-related symptoms, prior platinum status, and current functional status, concludes Crafton.
SELECTED
LANGUAGE


Sarah Crafton, MD, gynecologic oncologist, Allegheny Health Network, discusses optimizing treatment selection in recurrent ovarian cancer.
 
Platinum-sensitivity should be used to guide treatment selection in the recurrent setting, says Crafton. Notably, a variety of platinum-based therapies and targeted therapies are available to patients with platinum-sensitive disease. and platinum-resistant disease.
 
The National Comprehensive Cancer Network publishes a list of available agents for patients with platinum-sensitive and platinum-resistant disease. The decision of which treatment to pursue should be based on previous toxicities, disease-related symptoms, prior platinum status, and current functional status, concludes Crafton.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x